2011
DOI: 10.1016/s1474-4422(11)70108-9
|View full text |Cite
|
Sign up to set email alerts
|

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

7
388
1
9

Year Published

2012
2012
2023
2023

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 540 publications
(405 citation statements)
references
References 24 publications
7
388
1
9
Order By: Relevance
“…Despite successfully reducing angiographic vasospasm, long-term patient outcome was not affected by administration of the non-glucocorticoid 21-aminosteroid tirilazad 11 or the endothelin receptor antagonist clazosentan. 12 It may be that, beyond examining short-term preclinical outcomes (such as early brain injury and cerebral vasospasm), the successful translation of putative therapies would be predicted by evaluation of long-term neurobehavioral outcomes in preclinical models, 13 as recommended by the Stroke Therapy Academic Industry Roundtable criteria. 14 Experimental SAH research has thus sought to model long-term neurobehavioral outcomes and elucidate the mechanisms responsible.…”
Section: Introductionmentioning
confidence: 99%
“…Despite successfully reducing angiographic vasospasm, long-term patient outcome was not affected by administration of the non-glucocorticoid 21-aminosteroid tirilazad 11 or the endothelin receptor antagonist clazosentan. 12 It may be that, beyond examining short-term preclinical outcomes (such as early brain injury and cerebral vasospasm), the successful translation of putative therapies would be predicted by evaluation of long-term neurobehavioral outcomes in preclinical models, 13 as recommended by the Stroke Therapy Academic Industry Roundtable criteria. 14 Experimental SAH research has thus sought to model long-term neurobehavioral outcomes and elucidate the mechanisms responsible.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, this paradigm has been challenged, leading to a reevaluation of the causal relationship between angiographically defined vasospasm of surface conduit arteries and SAH-induced morbidity and mortality (5)(6)(7). Supporting this change in sentiment, clinical trials have found that the endothelin-1A receptor antagonist clazosentan significantly decreased the incidence of large-artery vasospasm but failed to improve outcome in SAH patients (8,9). Additional mechanisms that may contribute to SAH-induced DINDs include early brain injury, inflammation, cortical spreading depression, and focal cortical infarcts arising from perfusion deficiencies within the microcirculation (5,6,10,11).…”
mentioning
confidence: 99%
“…[6][7][8] However, the stenosis of the spastic artery alone cannot fully explain the subsequent development of DCI, as not all patients with CVS, detected either radiologically or with transcranial Doppler (TCD), develop DCI. [8][9][10] For this reason, assessment of changes in the cerebral microvasculature distal to spastic vessels may be important. However, previous studies have yielded conflicting results.…”
Section: Introductionmentioning
confidence: 99%